Interesting points Joel. Regarding non-dihdropyridine CCBs, this is a still a relatively unanswered question whether they offer specific advantages over DHP-CCBs. At one time, I heard Bayer (promoting Adalat XL at the time) was considering a head-to-head trial with diltiazem XC. But of course, it never happened and so the theory never progressed beyond George Bakris' original work (a good article to add this repository). The apparent advantage of DHPs over non-DHPs for blood pressure potency also didn't help the cause of non-DHPs. Jordan
My pleasure. I hope you like it. We are always adding new material to the site. For older material, it's probably best to use flash on a desktop computer. Newer resources work on all platforms. Jordan